Cyclooxygenase-2 Expression in Intrahepatic Cholangiocarcinoma.
- Author:
Koo Yong HAHN
1
;
Seong Woo HONG
;
Yun Kyung KANG
;
Tae Gil HEO
;
Yeo Goo CHANG
;
In Wook PAIK
;
Hyucksang LEE
Author Information
1. Department of Surgery, Seoul Paik Hospital, Inje University, Seoul, Korea. lib0196@thrunet.com
- Publication Type:Original Article
- Keywords:
Intrahepatic cholangiocarcinoma;
Cyclooxygenase-2;
Carcinogenesis
- MeSH:
Bile Ducts;
Carcinogenesis;
Carcinogens;
Cholangiocarcinoma*;
Cyclooxygenase 2*;
Cytokines;
Epithelium;
Humans;
Hyperplasia;
Inflammation;
Intercellular Signaling Peptides and Proteins;
Liver;
Oncogenes;
Prostaglandin-Endoperoxide Synthases;
Risk Factors
- From:Korean Journal of Hepato-Biliary-Pancreatic Surgery
2003;7(1):102-107
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: Cyclooxygenase (COX)-2 levels are elevated in several types of human cancer tissues. COX-2 is not constitutively expressed by most normal tissues, but it is rapidly induced by certain inflammatory cytokines, tumor promoters, growth factors and oncogenes. Inflammation is important risk factor for intrahepatic cholangiocarcinoma. Therefore, this study was aimed to evaluate the role of COX-2 in intrahepatic cholangiocarcinoma development. METHODS: 18 intrahepatic cholangiocarcinoma patients was conducted in this study. COX-2 expression was investigated by immunohistochemical staining in resected liver specimen that involved 47 hyperplasia, 30 low-grade dysplasia, 38 high- grade dysplasia and 18 cancer. The relationship of clinicopathological factor and COX-2 expression of cancer was evaluated. RESULTS: COX-2 expression was not observed in normal bile duct epithelium. COX-2 expression in high-gade dysplasia was higher than in low-grade dysplasia. COX-2 expression in cancer was higher than in hyperplasia, low-grade and high grade dysplasia. There was no significant correlation between clinicopathological factors and COX-2 expression in cancer. CONCLUSION: These findings suggest that COX-2 may play a role in the early and late carcinogensis of intrahepatic cholangiocarcinoma.
